5872 - Everolimus (Answered)

Greg Mulholland
To ask the Secretary of State for Health, what discussions he has had with NHS England and NICE on the timescale for approving a commissioning policy for Everolimus.

George Freeman

NHS England is currently developing a policy for the provision of everolimus for tuberous sclerosis for complex related renal angiomyolipoma and also one for the provision of everolimus for subependymal giant cell astrocytoma. These two policies will both be considered as in-year items for the specialised services work programme for 2015/16. This was communicated in a Specialised Services Circular on 2 July 2015, a copy of which is attached.

There are no plans to ask the National Institute for Health and Care Excellence to assess everolimus for use in treating tuberous sclerosis complex through either its technology appraisal or highly specialised technology work programmes.

Although NHS England currently does not commission everolimus routinely, it continues to consider funding this treatment in exceptional and/or critically urgent clinical circumstances.